Spotlight Correspondence

Leukemia (2005) 19, 132–134. doi:10.1038/sj.leu.2403453 Published online 28 October 2004

Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib

R G Piazza1,2, V Magistroni1, M Gasser3, F Andreoni1, A Galietta1, L Scapozza3 and C Gambacorti-Passerini1,4

  1. 1Department of Experimental Oncology, National Cancer Institute, Milan, Italy
  2. 2University of Milano Bicocca, S Gerardo Hospital, Monza
  3. 3Department of Chemistry and Applied BioSciences at the Swiss Federal Institute of Technology, Zurich, Switzerland
  4. 4Department of Internal Medicine, Section of Hematology, University of Milano Bicocca, San Gerardo Hospital, Monza

Correspondence: Dr C Gambacorti-Passerini, Department of Experimental Oncology, National Cancer Institute, Via Venezian 1, Milan 20133, Italy. Fax: +39 2 2390 3237; E-mail: carlo.gambacorti@istitutotumori.mi.it

Received 24 November 2003; Accepted 4 June 2004; Published online 28 October 2004.

Top

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated

REVIEWS

Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein

Nature Reviews Neuroscience Review (01 Dec 2002)

NEWS AND VIEWS

Inhibitors of Bcr-abl. breaking new ground again

Nature Chemical Biology News and Views (01 Feb 2006)

Extra navigation

.

naturejobs

ADVERTISEMENT